Table 2 Baseline characteristics in relation to poor prognosis six months after acute cerebral infarction.
All patients | Poor prognosis | Good prognosis | P value | |
---|---|---|---|---|
Age (years) | 67.77 ± 7.22 | 69.32 ± 5.02 | 67.18 ± 7.82 | 0.001 |
Male | 400 (64.41%) | 122 (65.59%) | 278 (62.53%) | 0.524 |
Body mass index (kg/m2) | 25.07 ± 1.77 | 25.34 ± 1.63 | 24.97 ± 1.81 | 0.020 |
Systolic blood pressure (mmHg) | 140.53 ± 26.12 | 138.11 ± 24.63 | 141.45 ± 26.64 | 0.155 |
Diastolic blood pressure (mmHg) | 80.03 ± 14.23 | 79.27 ± 14.74 | 80.32 ± 14.03 | 0.413 |
SmokerAlcohol | 335 (53.95%) | 104 (55.91%) | 231 (53.10%) | 0.520 |
Admission time (hours) | 339 (54.43%) | 111 (59.68%) | 227 (52.18%) | 0.086 |
Blood-collection time (hours) | 5.90 (4.60–7.50) | `5.50 (4.70–6.90) | 5.20 (4.40–7.20) | 0.254 |
Comorbidity | 6.70 (5.50–8.10) | 6.20 (5.30–8.00) | 6.40 (5.10–8.30) | 0.510 |
Diabetes mellitus | ||||
Hypertension | 219 (35.27%) | 77 (41.40%) | 142 (32.64%) | 0.036 |
Coronary heart disease | 357 (57.49%) | 102 (54.84%) | 255 (58.62%) | 0.252 |
Dyslipidemia | 202 (32.53%) | 66 (35.48%) | 136 (31.26%) | 0.304 |
Treatment | 317 (51.05%) | 101 (54.30%) | 216 (49.66%) | 0.289 |
Thrombolysis | ||||
Antiplatelet | 193 (64.90%) | 51 (27.42%) | 142 (32.64%) | 0.198 |
Statins | 403 (64.90%) | 116 (62.37%) | 287 (65.98%) | 0.388 |
Anticoagulant | 278 (26.09%) | 91 (48.92%) | 187 (42.99%) | 0.173 |
GLP-1 agonists | 74 (11.92%) | 19 (5.38%) | 55 (7.36%) | 0.392 |
SGLT2 inhibitors | 37 (5.96%) | 15 (8.06%) | 22 (5.06%) | 0.147 |
NIHSS score | 115 (18.52%) | 42 (22.58%) | 73 (16.78%) | 0.088 |
Stroke etiology | 13.00 (7.00–16.00) | 14.00 (12.00–17.00) | 14.00 (12.00–16.00) | 0.001 |
Small-vessel occlusive | 0.801 | |||
Large-vessel occlusive | 164 (26.41%) | 47 (25.27%) | 117 (26.90%) | |
Cardioembolic | 198 (31.99%) | 56 (30.11%) | 142 (32.64%) | |
Others | 125 (20.13%) | 41 (22.04%) | 84 (19.31%) | |
Infarction volume (cm3) | 123 (19.81%) | 42 (22.58%) | 92 (21.15%) | |
TOAST subtype | 34.60 (23.90–78.00) | 38.85 (24.98–91.50) | 33.80 (22.80–66.40) | 0.046 |
Large artery atherosclerosis | 0.529 | |||
Small artery occlusions | 238 (38.33%) | 63 (33.87%) | 168 (38.62%) | |
Cardioembolism | 305 (49.11%) | 97 (52.15%) | 212 (48.74%) | |
Infarct location | 78 (12.56%) | 26 (13.98%) | 55 (12.64%) | |
Anterior circulation infarct | 0.078 | |||
Posterior circulation infarct | 316 (50.89%) | 101 (54.30%) | 215 (49.43%) | |
Lacunar infarct | 182 (29.31%) | 43 (23.12%) | 139 (31.95%) | |
Laboratory data | 123 (19.81%) | 42 (22.58%) | 81 (18.62%) | |
Serum triglycerides levels (mg/dL) | 102.23 ± 30.94 | |||
Serum total cholesterol levels (mg/dL) | 212.93 ± 50.03 | 102.02 ± 31.77 | 101.31 ± 30.65 | 0.918 |
Serum HDL-c levels (mg/dL) | 49.48 ± 16.18 | 217.10 ± 41.46 | 211.34 ± 52.88 | 0.201 |
Serum LDL-c levels (mg/dL) | 136.58 ± 42.53 | 50.60 ± 16.53 | 49.05 ± 16.04 | 0.288 |
Serum glucose levels (mg/dL) | 117.53 ± 42.91 | 138.04 ± 36.11 | 136.03 ± 44.75 | 0.602 |
Serum PDMPs levels (ng/L) | 26.73 (21.59–33.83) | 124.48 ± 40.60 | 114.88 ± 43.06 | 0.013 |
Platelet count (× 109/L) | 239.00 (178.00–302.00) | 30.92 (25.40–35.26) | 24.94 (19.37–31.61) | < 0.001 |
APTT (s) | 28.04 ± 4.58 | 251.00 (181.75–306.00) | 239.00 (178.00–300.00) | 0.007 |
TT (s) | 12.09 ± 3.28 | 28.34 ± 4.29 | 27.93 ± 4.69 | 0.319 |
Serum fibrinogen levels (g/L) | 4.27 ± 1.55 | 12.48 ± 4.18 | 11.95 ± 2.86 | 0.069 |
4.46 ± 1.45 | 4.20 ± 1.59 | 0.066 |